Abstract Epstein-Barr virus (EBV), a γ-herpesvirus, is the first identified oncogenic virus,
which establishes permanent infection in humans. EBV causes infectious mononucleosis …

Effective tumor treatment depends on optimizing drug penetration and accumulation in
tumor tissue while minimizing systemic toxicity. Nanomedicine has emerged as a key …

The recent emergence of a causal link between Epstein-Barr virus (EBV) and multiple
sclerosis has generated considerable interest in the development of an effective vaccine …

Middle East respiratory syndrome coronavirus (MERS-CoV) is a betacoronavirus that
causes severe respiratory illness in humans. There are no licensed vaccines against MERS …

Epstein–Barr virus (EBV) is an oncogenic virus infecting more than 95% of the world's
population. After primary infection—responsible for infectious mononucleosis in young …

Herpesviruses are among the most successful viruses found in human populations. They
establish lifelong latent infections, which are punctuated by recurrent reactivations. The entry …

Nanotechnology carriers have become common in pharmaceutical products because of
their benefits to drug delivery, including reduced toxicities and improved efficacy of active …

Epstein-Barr virus (EBV) is closely associated with cancer, multiple sclerosis, and post-acute
coronavirus disease 2019 (COVID-19) sequelae. There are currently no approved …

Epstein-Barr virus (EBV) is associated with several malignancies, neurodegenerative
disorders and is the causative agent of infectious mononucleosis. A vaccine that prevents …

Self‐assembling polyhedral protein biomaterials have gained attention as engineering
targets owing to their naturally evolved sophisticated functions, ranging from protecting …